Phaseline

Companies › Daiichi Sankyo

Daiichi Sankyo: clinical trials, targets and expected readouts

22 active drug programs in 78 registered trials: 44 Phase 1, 20 Phase 3, 14 Phase 2; Oncology, Gastroenterology, Neurology; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Ifinatamab deruxtecan (DS-7300a, I-DXd)
Anti-B7H3 antibody-drug conjugate
B7H3, DLL3Phase 3Small Cell Lung Cancer; Esophageal Squamous Cell Carcinoma; Extensive-stage Small-cell Lung Cancer; Advanced Solid Tumor …Dec 2026
Datopotamab Deruxtecan
Tumor-associated calcium signal transducer 2 binding agent; DNA topoisomerase I inhibitor
TACSTD2, TOP1Phase 3Non-small Cell Lung Cancer; Metastatic Non Small Cell Lung Cancer; Urothelial Cancer; Advanced or Metastatic NSCLC …Dec 2026
Patritumab Deruxtecan
Receptor tyrosine-protein kinase erbB-3 binding agent; DNA topoisomerase I inhibitor
ERBB3, TOP1Phase 3Nonsquamous Non-small Cell Lung Cancer; Non-Small Cell Lung Cancer Metastatic; Advanced Solid Tumor; Non-Small Cell Lung Cancer (NSCLC) …Dec 2026
Pexidartinib
Macrophage colony stimulating factor receptor inhibitor; Tyrosine-protein kinase receptor FLT3 inhibitor; Stem cell growth factor receptor inhibitor
CSF1R, FLT3, KITPhase 3Tenosynovial Giant Cell Tumor; Neurofibroma, PlexiformMar 2027
Trastuzumab Deruxtecan
Receptor protein-tyrosine kinase erbB-2 binding agent; DNA topoisomerase I inhibitor
ERBB2, TOP1Phase 3Breast Cancer; Gastric Cancer, Adenocarcinoma; Advanced Cancer; Gastric Cancer …Mar 2027
Quizartinib
Macrophage colony stimulating factor receptor inhibitor; Tyrosine-protein kinase receptor FLT3 inhibitor; Stem cell growth factor receptor inhibitor
CSF1R, FLT3, KIT, PDGFRB, PDGFRAPhase 3Leukemia; Acute Myeloid Leukemia; Hepatic Impairment; Acute Myeloid Leukemia, Adult …May 2027
raludotatug deruxtecan (R-DXd; DS-6000a)–Phase 2Solid Cancer; Advanced Solid Tumor; Renal Cell CarcinomaDec 2026
DS-5141b (Renadirsen)
Antisense oligonucleotide targeting dystrophin pre-mRNA
DYSTROPHINPhase 2Duchenne Muscular DystrophyJan 2027
DS-1001b
Isocitrate dehydrogenase [NADP] cytoplasmic inhibitor
IDH1Phase 2WHO Grade II GliomaFeb 2027
Valemetostat Tosylate
EZH1/2 dual inhibitor
EZH1, EZH2, KDM1APhase 2Relapsed/Refractory Peripheral T-Cell Lymphoma; Non-small Cell Lung Cancer; Advanced Solid Tumor; Lymphoma, B-Cell …Mar 2028
DS-1055a–Phase 1Solid TumorJul 2027
DS-3201b–Phase 1Lymphoma, MalignantDec 2027
DS1025a–Phase 1Advanced Solid TumorJan 2028
Valemetostat (DS-3201b)
Histone deacetylase inhibitor
HDAC (class I/II)Phase 1Metastatic Castration-resistant Prostate Cancer; Aggressive Variant Prostate Carcinoma; Extensive-stage Small-cell Lung Cancer; Lymphoma …Jan 2028
DS9051b
Unclear - code-named investigational drug
–Phase 1Advanced or Metastatic Adrenocortical CarcinomaMar 2028
DS-3939a–Phase 1Advanced Solid Tumor; Solid TumorAug 2028
DS3610a–Phase 1Solid TumorsSep 2028
DS-2243a–Phase 1Solid TumorsNov 2028
DS-1103a–Phase 1Advanced Solid Tumor; Solid TumorMay 2029
Olomorasib
KRAS G12C inhibitor
KRASPhase 1Urothelial CancerSep 2029
DS5361b–Phase 1Advanced Solid TumorMar 2030
DS3790a–Phase 1Hematological MalignanciesNov 2030

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT03529110Trastuzumab DeruxtecanPhase 3Breast CancerOncologyMay 2021
NCT03734029Trastuzumab DeruxtecanPhase 3Breast CancerOncologyJan 2022
NCT04842877Valemetostat TosylatePhase 2Lymphoma, B-CellOncologyDec 2024
NCT04704934Trastuzumab DeruxtecanPhase 3Gastric Cancer, AdenocarcinomaOncologyAug 2026
NCT06740799QuizartinibPhase 1Hepatic ImpairmentGastroenterologyOct 2026
NCT05280470Ifinatamab deruxtecan (DS-7300a, I-DXd)Phase 2Extensive-stage Small-cell Lung CancerOncologyDec 2026
NCT04707248raludotatug deruxtecan (R-DXd; DS-6000a)Phase 1Renal Cell CarcinomaOncologyDec 2026
NCT05338970Patritumab DeruxtecanPhase 3Nonsquamous Non-small Cell Lung CancerOncologyDec 2026
NCT04526691Datopotamab DeruxtecanPhase 1Advanced or Metastatic NSCLCOncologyDec 2026
NCT04388852Valemetostat (DS-3201b)Phase 1Aggressive Variant Prostate CarcinomaOncologyDec 2026
NCT02390752PexidartinibPhase 1Neurofibroma, PlexiformOncologyDec 2026
NCT04619004Patritumab DeruxtecanPhase 2Non-Small Cell Lung Cancer MetastaticOncologyJan 2027
NCT06807632Valemetostat (DS-3201b)Phase 1Extensive-stage Small-cell Lung CancerOncologyJan 2027
NCT04433234DS-5141b (Renadirsen)Phase 2Duchenne Muscular DystrophyNeurologyJan 2027
NCT04656652Datopotamab DeruxtecanPhase 3Non-small Cell Lung CancerOncologyFeb 2027
NCT04458272DS-1001bPhase 2WHO Grade II GliomaOncologyFeb 2027
NCT04042701Trastuzumab DeruxtecanPhase 1Breast CancerOncologyMar 2027
NCT04488822PexidartinibPhase 3Tenosynovial Giant Cell TumorOncologyMar 2027
NCT04145622Ifinatamab deruxtecan (DS-7300a, I-DXd)Phase 1Advanced Solid TumorOncologyApr 2027
NCT03793478QuizartinibPhase 1Acute Myeloid LeukemiaOncologyMay 2027
NCT04419532DS-1055aPhase 1Solid TumorOncologyJul 2027
NCT06362252Ifinatamab deruxtecan (DS-7300a, I-DXd)Phase 1Extensive Stage-small Cell Lung CancerOncologyJul 2027
NCT03260491Patritumab DeruxtecanPhase 1Non-Small Cell Lung Cancer (NSCLC)OncologyJul 2027
NCT06172478Patritumab DeruxtecanPhase 2Advanced Solid TumorOncologySep 2027
NCT05683171Valemetostat (DS-3201b)Phase 1LymphomaOncologySep 2027
NCT05950945Trastuzumab DeruxtecanPhase 3Breast CancerOncologyOct 2027
NCT04676477Patritumab DeruxtecanPhase 1Non-Small Cell Lung Cancer (NSCLC)OncologyDec 2027
NCT04128748QuizartinibPhase 1Acute Myeloid LeukemiaOncologyDec 2027
NCT04493138QuizartinibPhase 1Chronic Myelomonocytic LeukemiaOncologyDec 2027
NCT04047641QuizartinibPhase 1Acute Myeloid LeukemiaOncologyDec 2027
NCT02732275DS-3201bPhase 1Lymphoma, MalignantOncologyDec 2027
NCT03661307QuizartinibPhase 1Acute Myeloid LeukemiaOncologyJan 2028
NCT07681882DS1025aPhase 1Advanced Solid TumorOncologyJan 2028
NCT06203210Ifinatamab deruxtecan (DS-7300a, I-DXd)Phase 3Small Cell Lung CancerOncologyJan 2028
NCT06294548Valemetostat (DS-3201b)Phase 1Hepatocellular CarcinomaOncologyJan 2028
NCT07244341Valemetostat (DS-3201b)Phase 1Metastatic Castration-resistant Prostate CancerOncologyJan 2028
NCT06174987Trastuzumab DeruxtecanPhase 3Advanced CancerOncologyFeb 2028
NCT06161025raludotatug deruxtecan (R-DXd; DS-6000a)Phase 2Solid CancerOncologyFeb 2028
NCT07189403DS9051bPhase 1Advanced or Metastatic Adrenocortical CarcinomaOncologyMar 2028
NCT06644768Valemetostat TosylatePhase 1Non-small Cell Lung CancerOncologyMar 2028
NCT06644781Ifinatamab deruxtecan (DS-7300a, I-DXd)Phase 3Esophageal Squamous Cell CarcinomaOncologyJun 2028
NCT06731478Trastuzumab DeruxtecanPhase 3Gastric CancerOncologyJun 2028
NCT06824168QuizartinibPhase 2Acute Myeloid LeukemiaOncologyJun 2028
NCT06262438QuizartinibPhase 2Acute Myeloid Leukemia in ChildrenOncologyJun 2028
NCT04622319Trastuzumab DeruxtecanPhase 3HER2-Positive Primary Breast CancerOncologyJun 2028
NCT06330064Ifinatamab deruxtecan (DS-7300a, I-DXd)Phase 1Recurrent or Metastatic Solid TumorsOncologyJul 2028
NCT05875168DS-3939aPhase 1Advanced Solid TumorOncologyAug 2028
NCT07159126DS3610aPhase 1Solid TumorsOncologySep 2028
NCT06769490QuizartinibPhase 1Acute Myeloid LeukemiaOncologySep 2028
NCT06819007Trastuzumab DeruxtecanPhase 3Ovarian CancerOncologyNov 2028
NCT06244485Trastuzumab DeruxtecanPhase 1Advanced Solid TumorOncologyNov 2028
NCT06244485Datopotamab DeruxtecanPhase 1Advanced Solid TumorOncologyNov 2028
NCT06244485Valemetostat TosylatePhase 1Advanced Solid TumorOncologyNov 2028
NCT06644755DS-2243aPhase 1Solid TumorsOncologyNov 2028
NCT07015697Trastuzumab DeruxtecanPhase 1Recurrent or Metastatic Solid TumorsOncologyDec 2028
NCT05555732Datopotamab DeruxtecanPhase 3Metastatic Non Small Cell Lung CancerOncologyMay 2029
NCT05765851Trastuzumab DeruxtecanPhase 1Advanced Solid TumorOncologyMay 2029
NCT05765851DS-1103aPhase 1Advanced Solid TumorOncologyMay 2029
NCT07129993Datopotamab DeruxtecanPhase 2Urothelial CancerOncologyJun 2029
NCT04703192Valemetostat TosylatePhase 2Relapsed/Refractory Peripheral T-Cell LymphomaOncologyJun 2029

The 60 nearest readouts of 78 trials; the rest in the app.

From the company's SEC filings

Complete response letters from FDA

Targets

TOP1 (3) CSF1R (2) FLT3 (2) KIT (2) B7H3 (1) DLL3 (1) ERBB3 (1) ERBB2 (1) TACSTD2 (1) KRAS (1) PDGFRB (1) PDGFRA (1)

Companies with the same targets

Novartis AstraZeneca Deciphera Pharmaceuticals Blueprint Medicines Merck & Co. (MSD) Gossamer Bio USA Xynomic Pharmaceuticals Etnova Therapeutics Jiangsu HengRui Medicine Roche

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.